Welcome Customer !

Membership

Help

Beijing Saitaike Biotechnology Co., Ltd
Custom manufacturer

Main Products:

instrumentb2b>News

Beijing Saitaike Biotechnology Co., Ltd

  • E-mail

    selina@cy-tech.com.cn

  • Phone

    13426082940

  • Address

    1-2F, Building C, Xisanqi Cultural and Technological Park, No. 27 Xixiaokou Road, Qinghe Xiaoying, Haidian District, Beijing

Contact Now
The nationwide tour of the chemical reprogramming induced human pluripotent stem cell (hCiPS) technology training course has been launched, and the pre registration channel has been opened
Date: 2023-08-11Read: 0


BeiCellTMThe human chemistry reprogramming induced pluripotent stem cell assay kit is based on the latest breakthrough achievement of Professor Deng Hongkui's team at Peking UniversityUsing chemical small molecules to induce human adult cells to transform into pluripotent stem cells(Nature,2022; Cell Stem Cell,2023The independently developed next-generation technology for the preparation of pluripotent stem cells has solved the bottleneck problem in the underlying technology for the development of stem cells and regenerative medicine in China.

Chemical reprogramming technology is a non integrated method that avoids safety issues caused by genetic modification operations, and is easy and flexible to operate. It has strong spatiotemporal regulation and reversible effects, and can accurately manipulate the process of cell reprogramming. In addition, the chemical reorganization induction technology has clear components, does not rely on serum, and does not rely on feeder layer cells. These properties better meet the needs of clinical applications and provide a basis for establishing a human body that meets clinical application standardsCiPSThe cell line laid the foundation.

1)In terms of safety, chemical small molecules do not integrate into the genome and have no immunogenicity. Previously in miceCiPSIt has been demonstrated in cells that using miceCiPSChimeric mice produced by cells exhibit long 6During the observation period of months, no tumors were generated and all patients were healthy and alive. At the same time, peopleCiPSIslet cells derived from cell differentiation were transplanted into mouse and non-human primate models, and no tumor formation was found after long-term observation;

2)In terms of induction cycle, efficiency, and universality, chemical reprogramming technology can30Within days (shortest)16The induction can be completed in just a few days, and the induction efficiency can reach31%Currently tested at least20Somatic cells from individuals with different genetic backgrounds and ages can be efficiently induced;

3)In terms of clinical application, chemical reprogramming technology is simple to operate and can achieve somatic cell reprogramming only through fluid exchange. In addition, a series of characteristics such as reversible small molecule interactions, convenient synthesis and storage, and ease of standardized production have enabled people toCiPSCells have irreplaceable advantages in standardized and large-scale production, which can better meet clinical needs.

According to the latest report, Peking University Stem Cell Center and Tianjin First Central Hospital have collaborated to successfully complete an international projectShou Example1Induction of pluripotent stem cells by chemical reprogramming in type 2 diabetes subjects(Chemically induced Pluripotent Stem Cell, CiPSC)Differentiated islet like cell transplantation surgery.CiPSCIt can proliferate infinitely and efficiently differentiate into well functioning pancreatic islet cells, indicatingCiPSCInduced islet cell transplantation has the potential to become a cure1The ideal scheme for type diabetes, and this technology can be applied to patients with pancreatic islet failure2Type diabetes patients. This successful example once again provesCiPSCell induction technology has extremely broad application prospects in fields such as cell therapy, drug screening, and disease modeling.

At present, Beijing Beiqi Biopharmaceutical Co., Ltd. (hereinafter referred to as Beiqi Biotech) is responsible for product transformation of this cutting-edge technology. In order to enable more researchers to understand this new technology and accelerate its application in scientific research and clinical treatment, Beiqi Biotechnology will hold training courses on chemical reprogramming induced human pluripotent stem cell technology in Shanghai, Suzhou, Guangzhou, Chengdu and other places (training courses will not charge training fees). This training course is hosted by Beiqi Biotechnology and co organized by Beijing Saitaike Biotechnology Co., Ltd. We welcome teachers and students who are interested in this technology to sign up and participate actively, and work together to promote China's leapfrog development in the field of stem cells!

The pre registration channel for the training class has been opened. Interested teachers and students can refer to the training schedule below for pre registration. Please indicate the location of the training class you wish to attend when registering. For specific information, please call us for more details!


region

Proposed class opening date

First Stop

Suzhou

2023.9.20

Second Station

Shanghai

2023.9.21

the third station

Guangzhou

2023-10.19

The fourth stop

Chengdu

2023.11.16